Navigation Links
Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
Date:4/26/2011

SUNNYVALE, Calif., April 26, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has received a $7 million milestone payment for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454 from Les Laboratoires Servier ("Servier") based on an ex-US collaboration agreement signed in April of 2009.  Over the past two years Servier has engaged in several exploratory Phase I/II trials in solid tumors and hematologic malignancies.  Servier is now focused on its Phase II programs to enable the registration pathway for PCI-24781 / S 78454.

"Five phase I and I/II trials are ongoing in Europe in lymphomas and solid tumors. The first results are very encouraging in terms of clinical activity and safety profile and we plan to start soon new combination trials," said Stephane Depil MD, PhD, Director of Oncology Research and Development Unit at Servier.

"Servier is delighted to work with Pharmacyclics under this partnership," said Emmanuel Canet MD, PhD, Servier's President, Research and Development. "The molecule PCI-24781 / S 78454 has performed well in a variety of early stage trials and exceeds our expectations. We plan to further expand the clinical development of PCI-27481 / S 78454."

Mr. Robert Duggan, Pharmacyclics CEO & Chairman, added, "we are very pleased with the progress of PCI-24781 / S 78454 and the alliance with Servier. We are looking forward to work closely with our partner to advance this molecule to the market."

About HDAC Inhibitor, PCI-24781 / S 78454 is an orally-bioavailable histone deacetylase (HDAC) inhibitor that is currently in multiple clinical trials in the United States and the European Union.  The US trials include a Phase II trial in patients with recurrent lymphomas and a Phase I/II trial in sarcoma patients (in combination with doxorubicin, an anti tumor agent). Hi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Secures $5.0 Million in Debt Financing
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
8. Pharmacyclics Announces Subscription Price for Rights Offering
9. Pharmacyclics, Inc. Rights Offering Oversubscribed
10. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
11. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... approves Intercell,s first marketed product, a new vaccine against ... product launch in the U.S. planned for Q2 2009VIENNA, ... that the U.S. Food and Drug Administration (FDA) approved ... Encephalitis (JE). The initial target for use of Intercell,s ...
... Mylan Inc. (Nasdaq: MYL ) today ... which it holds a 71.2% controlling interest, has received ... Drug Administration (FDA) under the President,s Emergency Plan for ... (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 ...
... WALTHAM, Mass., March 30 Inverness Medical Innovations, Inc. (NYSE: ... to take charge of their health at home through the ... dividend of $3.00 per share on its Series B Convertible ... in shares of Series B stock in an amount per ...
Cached Biology Technology:Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... fires are visible in in this image of the ... of these were most likely intentionally set in order ... a forest or stand of trees where the land ... deforestation include conversion of forestland to farms, ranches, or ... dark green of the Amazon Rainforest in the middle ...
(Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Scientists learn more about rare skin cancer that killed Bob Marley 2
... Increasing block-rate water budgets are an innovative type ... block sizes are based on household characteristics, environmental conditions, ... to what constitutes "efficient" water use given those characteristics ... set relatively low for the most essential uses of ...
... the most serious are poverty, the growing demand for ... to satisfy the growing demand for wood, forestry in ... the Russian Federation are the world,s largest reserve of ... will result in increasing availability of wood for material ...
... of data related to climate change are being compiled ... these many and various sources results in different climate ... data sets to arrive at a consensus regarding future ... December in the SIAM Journal on Uncertainty Quantification ...
Cached Biology News:An innovative approach to promote water use efficiency 2An innovative approach to promote water use efficiency 3Sustainable use of energy wood resources shows potential in North-West Russia 2Sustainable use of energy wood resources shows potential in North-West Russia 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4
... Kit is intended for quantitative detection of ... which can result from the gradual, nonenzymatic ... acid residues during storage or handling. Because ... monitoring of charge differences for detection, charge ...
...
... siRNA and miRNA Isolation Traditional mRNA ... mRNA and can result in the loss ... mirVana miRNA Isolation Kit purifies all RNA ... double-stranded. Through an enrichment procedure included in ...
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Biology Products: